Long-term immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is often treated with immunoglobulins, a costly therapy.
• Functional outcome monitoring is not consistently used in CIDP treatment.
• CIDP exhibits a heterogeneous clinical course, including spontaneous remissions.

Purpose of the Study:

• To evaluate the appropriateness of high-dose, first-line immunoglobulin treatment for CIDP.
• To review current clinical questions regarding CIDP management, including monitoring and alternative therapies.

Main Methods:

• Review of recent evidence on immunoglobulin dosing and efficacy in CIDP.
• Analysis of clinical trial data comparing immunoglobulins and corticosteroids.
• Discussion of treatment withdrawal and long-term therapy protocols.

Main Results:

• Limited evidence suggests lower immunoglobulin doses may be effective.
• No established correlations exist between effective immunoglobulin dose and patient factors.
• Corticosteroids may offer higher remission rates than immunoglobulins in some CIDP cases.

Conclusions:

• High-dose immunoglobulin therapy for CIDP warrants re-evaluation.
• Careful monitoring is crucial to prevent overtreatment with immunoglobulins.
• Corticosteroids represent a viable alternative for CIDP treatment, potentially offering better remission outcomes.